These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1790954)

  • 1. [Ototoxicity of cisplatin chemotherapy in patients with ovarian cancer].
    Beck E; Schuster M; Berg A; Jäger W; Wildt L; Lang N
    Gynakol Rundsch; 1991; 31 Suppl 2():280-5. PubMed ID: 1790954
    [No Abstract]   [Full Text] [Related]  

  • 2. [Ototoxic side effects in patients with ovarian cancer treated with cisplatin].
    Behling H; Spieske C; Krafft W
    Zentralbl Gynakol; 1988; 110(5):277-82. PubMed ID: 3376611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Ototoxicity of cisplatin in children with malignant diseases].
    Hadjilaskari P; Fengler R; Hartmann R; Henze G
    Klin Padiatr; 1989; 201(4):316-21. PubMed ID: 2779137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cisplatin ototoxicity. A clinical study].
    Schröder M; Laskawi R; Stennert E; Kühnle H; Thiele FW
    Laryngol Rhinol Otol (Stuttg); 1986 Feb; 65(2):86-9. PubMed ID: 3959692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
    Freilich RJ; Kraus DH; Budnick AS; Bayer LA; Finlay JL
    Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Monitoring hearing during ototoxic cisplatin therapy].
    Kluba J; Kluba U; von Specht H; Mittler U
    Padiatr Grenzgeb; 1990; 29(1):19-23. PubMed ID: 2342815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics.
    Ekborn A; Hansson J; Ehrsson H; Eksborg S; Wallin I; Wagenius G; Laurell G
    Laryngoscope; 2004 Sep; 114(9):1660-7. PubMed ID: 15475801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The incidence of hearing impairment after successful treatment of neuroblastoma.
    Simon T; Hero B; Dupuis W; Selle B; Berthold F
    Klin Padiatr; 2002; 214(4):149-52. PubMed ID: 12165893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatinum ototoxicity in children, long-term follow up.
    Al-Khatib T; Cohen N; Carret AS; Daniel S
    Int J Pediatr Otorhinolaryngol; 2010 Aug; 74(8):913-9. PubMed ID: 20846503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer.
    Fanning J; Hilgers RD
    Gynecol Oncol; 1993 Nov; 51(2):182-6. PubMed ID: 8276291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. cis-platinum ototoxicity in children.
    Weatherly RA; Owens JJ; Catlin FI; Mahoney DH
    Laryngoscope; 1991 Sep; 101(9):917-24. PubMed ID: 1886439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High dose cisplatin after failure of polychemotherapy containing cisplatin in ovarian cancer. Preliminary results.
    Bruzzone M; Conte PF; Chiara S; Carnino F; Giaccone G; Conio A; Bentivoglio G; Pescetto G; Rosso R
    Chemioterapia; 1985 Apr; 4(2):139-42. PubMed ID: 3891114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
    Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
    Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine.
    Sastry J; Kellie SJ
    Pediatr Hematol Oncol; 2005; 22(5):441-5. PubMed ID: 16020136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment by combined chemotherapy for recurrent ovarian cancer.
    Shershah S
    J Pak Med Assoc; 1985 Nov; 35(11):341-3. PubMed ID: 3935821
    [No Abstract]   [Full Text] [Related]  

  • 17. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis.
    Chan SH; Ng WT; Kam KL; Lee MC; Choi CW; Yau TK; Lee AW; Chow SK
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1335-42. PubMed ID: 18922648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose intensity in advanced ovarian cancer: have we answered the question?
    Fennelly D
    Clin Cancer Res; 1995 Jun; 1(6):575-82. PubMed ID: 9816018
    [No Abstract]   [Full Text] [Related]  

  • 19. [The value of platinum dose intensity in first-line therapy on subsequent disease follow-up of epithelial ovarian carcinoma].
    Gruböck K
    Wien Klin Wochenschr; 1994; 106(11):362-6. PubMed ID: 8053205
    [No Abstract]   [Full Text] [Related]  

  • 20. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
    Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
    J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.